Stockreport

Atossa gains on Rare Pediatric Disease status for Duchenne asset [Seeking Alpha]

Atossa Therapeutics, Inc.  (ATOS) 
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.atossagenetics.com
PDF If "Z"-Endoxifen is eventually approved, Atossa would be eligible for a Priority Review voucher that could be sold to another company. "Z"-Endoxifen is a selective es [Read more]